William Blair analyst Brandon Vazquez has maintained their bullish stance on ELAN stock, giving a Buy rating on July 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Elanco Animal Health’s strong performance and future potential. The company’s sales exceeded expectations by 5%, and EBITDA was 11% above estimates, indicating robust financial health. Additionally, Elanco’s management has increased its 2025 guidance, surpassing consensus expectations, which reflects confidence in the company’s growth trajectory.
Elanco’s innovation portfolio has shown remarkable progress, with sales more than doubling year-over-year. This growth has prompted an upward revision of full-year innovation sales expectations to between $720 million and $800 million, representing a 65% increase. Key products such as Zenrelia, Quattro, AdTab, and Experior/Bovaer have demonstrated positive momentum, reinforcing the company’s position for a multiyear cycle of improving growth and margins. With shares trading at 15 times the 2026 EPS estimate, Vazquez maintains a positive outlook on Elanco’s stock.
In another report released on July 23, UBS also maintained a Buy rating on the stock with a $18.00 price target.